Program|
Intro & Faculty|
Abstracts|
Registration|
Contact|
Supporters


Program

TRIALIST WORKSHOP

Day 1
   
MONDAY – 6th December 2010

Cancer cachexia

08:45-10:45
The patients of interest
Welcome & Introductions

a) Muscle wasting in cancer: the clinical & survial impact
b) Symptom generation and causes of death
in cancer cachexia
c) Defining patients with cancer cachexia using
weightloss & BMI
d) Trial challenges: dealing with poor compliance,
drop-outs & mortality
e) Recruitment strategies for cancer cachexia trials
f) Recruitment in academic centers in Europe
g) General moderated disucussion



10.45-11.05     Break

11.05-12.20
The approval process for cachexia
medicines: focus on endpoints
a) FDA statement
b) EMEA statement
c) NIH statement
d) Patient reported outcomes
e) General moderated discussion



12.20-13.00     Lunch break

13.30-14.20
Focus on endpoints
a) Assessment of body composition: challenges and solutions
b) Muscle function & exercise capacity tools
c) QoL assessment in cancer cachexia
d) Mortality & Morbidity- from power calculation to reality
e) Cachexia therapy as palliative care - learning
from past approvals
f) General moderated discussion



14.20-14.40     Break

14.40-16.40
Endpoints and results of ongoing and past trials - learning from experience
a) Anabolic interventions
b) Targeting muscle wasting
c) Other approaches
d) Anti-inflammatory therapies
e) Appetite stimulants
f) Nutrition approaches
g) General moderated discussion



16.40-17.00 Break

17.00-18.00
Other important consideration developing
anti-cachexia medicines
a) The value of anti-cachexia drugs in oncology
b) Co-medication problems
c) Safety considerations
d) General moderated discussion






Day 2     TUESDAY – 7th December 2010

Sarcopenia

8.45-10.50
Definition
a) Setting the stage on sarcopenia - definition, epidemiology
b) Sarcopenia vs. osteopenia
c) Sarcopenia vs. dynopenia vs. function
d) Effects of inactivity on muscle mass
e) Defining sarcopenia: US perspective
f) Defining sarcopenia: EU perspective
g) General moderated discussion on
sarcopenia definition



10.50-11.10     Break

11.10-13.00
Definition II
a) Past and current trials and their inclusion
and exclusion criteria
b) Sarcopenia research: the NIH perspective
c) Assessing muscle mass in sarcopenia trials
d) Functional testing in sarcopenia trials
e) FDA statement
f) EMEA Statement
e) General moderated discussion




Washington,
USA

December 6 & 7, 2010


Please note:
This event by invitation only.


Venue:
The Fairfax at Embassy Row
2100 Massachusetts Avenue,
NW Washington,
DC 20008,
USA
Tel: 202.835.2158
Fax: 202.736.1420

The Fairfax Hotel


Second day's program:

Tuesday program


Contact:
Society on Cachexia and Wasting Disorders (SCWD)
C/O MedEd Global Solutions
75, rue Guy Môquet
92240 Malakoff
France

Phone: (+33) 1 42 53 03 03
Fax: (+33) 1 42 53 03 02
Email: info@mededgs.com
    Program | Intro & Faculty | Abstracts | Registration | Contact | Supporters    

Copyright © 2009 MedEd Global Solutions:  www.mededgs.com
Website design and development:  www.netactif.fr